기존 tetrabenazine에서 개선 된 deutetrabenazine
에 대한 내용으로,
부작용이 다소 감소되었다고 하나 기존 테트라베나진과 비교 향상된 것인지는 좀 더 두고봐야할 것 같습니다. 테트라베나진과 성분이 거의 유사하여 기존 부작용들이 해결되지는 않았을 것 같은데 앞으로 좀더 개서되는 약들이 나오길 희망합니다.
아래 원문 첨부합니다.
Drug Eases Huntington's Disease Symptoms - WebMd 7-7-2016
Drug Eases Huntington's Disease Symptoms
med seems to have fewer side effects than current treatment,
News from HealthDay
Steven Reinberg HealthDay Reporter
July 7, 2016 (HealthDay News) - An experimental drug may help
the involuntary, sudden muscle movements associated with
disease, with fewer side effects, according to the results of a
trial. "Deutetrabenazine is not yet
FDA-approved, but assuming it
available, practicing clinicians may have another choice for their
patients," said lead researcher Dr. Samuel Frank. He is a
and instructor at Harvard Medical School in Boston.
involuntary movements associated with Huntington's disease are called
Huntington's disease is a fatal genetic disorder. It causes the
destruction of nerve cells in the brain. Symptoms vary from
to person. People who have Huntington's lose their physical and
abilities over 10 to 25 years. The disease has no cure, according to
Huntington's Disease Society of America (HDSA). Every child with a
with Huntington's disease has a 50 percent chance of carrying the
gene. Approximately 30,000 Americans have symptomatic Huntington's
More than 200,000 are at risk of inheriting the disease, the HDSA
choice of drugs to treat chorea should be based on safety,
cost to patients and the best chance of compliance, Frank
said. "The opportunity to possibly improve
quality of life should be part
the decision-making process as well," he said. "If approved by the
may provide another treatment option, making Huntington's
an increasingly treatable condition."
for the trial was provided by the maker of the drug, Auspex
a subsidiary of Teva Pharmaceutical Industries, Ltd.
) is the only
approved by the U.S. Food and Drug Administration for treating chorea
Huntington's disease, the study authors said. Although the drug is
tetrabenazine often has to be taken three times a day and can
side effects, such as sedation, fatigue, anxiety or nausea, the
the new study, Frank and his colleagues randomly assigned 90 patients
Huntington's disease and chorea to receive either deutetrabenazine or a
eight weeks, the dose of deutetrabenazine was increased to a level at
it was most effective. That dose was maintained over four weeks, the
found that deutetrabenazine reduces chorea, the hallmark movement
in Huntington disease," Frank said. "There was also an overall
in participants' condition and improvement in a quality-of-life
There was, however, no improvement in balance." The rate of side
was similar for the drug and a placebo, which included depression,
and akathisia (a movement disorder), the researchers found.
study findings were published July 5 in the Journal of the American
Association. Frank said larger trials are underway to assess the
safety and effectiveness of deutetrabenazine.
neurologist said he would like to have seen a head-to-head comparison
between deutetrabenazine and tetrabenazine.
"I wish they had included a
arm and a placebo arm," said Dr. Michael Geschwind. A
of neurology at the University of California, San Francisco, he
an editorial accompanying the study results.
a trial is needed to see which drug is superior, Geschwind said. "But
FDA approval, they only have to show it's better than placebo," he said.
at this trial and another that compared tetrabenazine with a
Geschwind found that both drugs appeared to be equally effective.
deutetrabenazine had fewer side effects, he said.
a patient is doing well on tetrabenazine and tolerating it well, I
consider changing it," Geschwind said. "But if I were starting a
patient and the drugs were similar in cost, I'm probably going to go to
new drug because out of the starting gate I'm probably going to have
5, 2016, Vol 316, No. 1
| July 5, 2016
for Treatment of Chorea in Huntington Disease
Michael D. Geschwind, MD, PhD1; Nick Paras, PhD1
this issue of JAMA, the Huntington Study Group (HSG), First-HD study
reports findings from a randomized trial examining use of a
form of tetrabenazine, called deutetrabenazine, for treatment of
in patients with Huntington disease.1
vesicular monoamine transporter type 2 inhibitor that depletes monoamines
dopamine, is used worldwide for the treatment of chorea and
Tetrabenazine was approved by the US Food and Drug Administration
for the treatment of chorea in Huntington disease, based on a prior